In the early 2000s, the Human Genome was fully sequenced and the post-genomic era was in full swing. This new era was all about understanding how genes interact together in healthy individuals and how these interactions go awry to cause disease.
1 Westmount Square, Suite 800
In 2000, taking advantage of the changing landscape of the genomics industry, we raised our second focused fund, GeneChem Therapeutics Venture Fund L.P. With committed capital of $136.5 million, the Therapeutics Fund's goal was to invest in companies leveraging the knowledge unveiled by the decryption of the Human Genome. We invested specifically in the development of therapeutics for proliferative disorders including cancer, infectious diseases, inflammation and diabetes, diseases for which there was an important unmet medical need, large market opportunity and where genomics had yet to make its mark.